Scinai Immunotherapeutics Ltd. (SCNI) shareholders
Close on Nov 17, 2026Market cap $1.29MP/E –Yield –
Ownership
Who owns Scinai Immunotherapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lck Jnk 1 LLC | 317,366 | 6.33% | 13G (passive) amendment | Apr 27, 2026 |
| Mark Angelo Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more | 93,274 | 9.90% | 13G (passive) | Mar 24, 2025 |
| Stone Daniel E. Joint filing with RK Stone Miami, LLC (7.12%) | 0 | 9.90% | 13G (passive) amendment | Jun 4, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Amir Reichman | Chief Executive Officer, Director | 711,637,600 | 5.13% | Jun 18, 2026 |
| Elad Mark | Chief Operating Officer | 160,355,016 | 1.16% | Mar 26, 2026 |
| Mark Germain | Director | 120,000,000 | 0.86% | Jun 18, 2026 |
| Yael Margolin | Director | 66,800 | 0.00% | Mar 18, 2026 |
| Uri Ben-Or | Director | 33,329,004 | 0.24% | Mar 18, 2026 |
| Samuel J. Moed | Director | – | – | Mar 18, 2026 |
| Adi Raviv | Director | 66,800 | 0.00% | Mar 18, 2026 |
| Jay Green | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amir Reichman Chief Executive Officer, Director | Jun 16, 2026 | Award | +400,000,000 | – | – | 711,637,600 |
| Mark Germain Director | Jun 16, 2026 | Award | +120,000,000 | – | – | 120,000,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scinai Immunotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 271,050 shares on Sep 15, 2026 over the last 90 days.
See a number that looks wrong?